MichaelWSchusterMD

Oncology • New York, NY

Hematologic Oncology

Professor of Hematology & Oncology, SUNY Stony Brook

Join to view full profile

Dr. Schuster is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Schuster's full profile

Already have an account?

Office
520 E 70th St
# Starr
New York, NY 10021
Phone+1 212-746-2119

Fax+1 212-746-3305

Education & Training

Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 1983 - 1987
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1980 - 1983
Geisel School of Medicine at DartmouthClass of 1980

Certifications & Licensure

CA State Medical License 1981 - Present
MA State Medical License 1982 - 2025
NY State Medical License 1987 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Newsday - Top Doctors on Long Island Castle Connolly, 2011-2020
America's Top Doctors for Cancer Castle Connolly, 2005-2020
Top Doctors: New York Metro Area Castle Connolly, 2003-2014, 2016-2020
America's Top Doctors Castle Connolly, 2002-2014, 2017-2020
New York Magazine: Top Doctors Castle Connolly, 2002-2014, 2016-2019
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients Start of enrollment: 2010 Jun 01
Terminated
Phase 2
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib Start of enrollment: 2010 Nov 01
Completed
Phase 4
A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Oct 01
Completed
Phase 3
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease Start of enrollment: 2012 Oct 01
Completed
Phase 2
A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation Start of enrollment: 2013 Aug 12
Completed
Phase 2
PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients Start of enrollment: 2015 Feb 01
Completed
Phase 2
A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2023 Jan 26
Active, not recruiting
Phase 1, Phase 2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Randomized Phase III SIERRA Trial ofI-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.
Boglarka Gyurkocza, Rajneesh Nath, Stuart Seropian, Hannah Choe, Mark R Litzow
Journal of Clinical Oncology. 2024-09-19
2 citations
Final outcomes from a phase 2 trial of posoleucel in allogeneic hematopoietic cell transplant recipients.
Sanjeet S Dadwal, Rajat Bansal, Michael W Schuster, Jean A Yared, Gary Douglas Myers
Blood Advances. 2024-09-10
8 citations
A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes.
Mikkael A Sekeres, Michael Schuster, Magalie Joris, Jürgen Krauter, Johan Maertens
Annals of Hematology. 2022-08-01

Abstracts/Posters

A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Mye...
Michael W. Schuster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients with Acute Myeloid LeukemiaClinically Relevant Abstract
Michael W. Schuster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Professional Memberships

American Society of Hematology - ASH
Member
American Society of Clinical Oncology - ASCO
Member